Treatment of Premenstrual Dysphoric Disorder with Selective Serotonin Reuptake Inhibitors

2003 ◽  
Vol 23 (9) ◽  
pp. 1131-1140 ◽  
Author(s):  
Andrea F. Luisi ◽  
Jayne E. Pawasauskas
Keyword(s):  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Premenstrual Dysphoric Disorder ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin

St. John's Wort (Hypericum Perforatum) as a Treatment for Premenstrual Dysphoric Disorder: Case Report

2003 ◽  
Vol 33 (3) ◽  
pp. 295-297 ◽  
Author(s):  
Kai-Lin Huang ◽  
Shih-Jen Tsai
Keyword(s):  
Side Effects ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Premenstrual Dysphoric Disorder ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
St John’S Wort ◽  
St John's Wort ◽  
Gastrointestinal Side Effects

Premenstrual dysphoric disorder (PMDD), a menstruous dysfunction, is characterized by profoundly depressed mood, and studies have shown that antidepressants are effective for PMDD. The authors describe a case of PMDD who was initially treated with selective serotonin reuptake inhibitors. Due to intolerable gastrointestinal side effects with selective serotonin reuptake inhibitors, St. John's wort (900 mg/day) was substituted and much improvement in PMDD symptoms was noted for at least five-month follow-up. The authors propose that St. John's wort could be an alternative medication for PMDD, especially for patients experiencing intolerable side effects with selective serotonin reuptake inhibitors.

scholarly journals Clinical Characteristics of Premenstrual Syndrome/Premenstrual Dysphoric Disorder Co-Morbid with Panic Disorder and the Effectiveness of Selective Serotonin Reuptake Inhibitors in Its Treatment

2019 ◽  
Vol 12 (1) ◽  
pp. 40-46
Author(s):  
Rossitza K. Iakimova ◽  
Daniil C. Aptalidis ◽  
Milena S. Pandova ◽  
Maria B. Stoyanova ◽  
Maya Y. Stoimenova-Popova
Keyword(s):  
Panic Disorder ◽  
Premenstrual Syndrome ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Psychological Symptoms ◽  
Somatic Symptoms ◽  
Premenstrual Dysphoric Disorder ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Effective Option

Summary Premenstrual syndrome (PMS) is often co-morbid with panic disorder (PD). Selective serotonin reuptake inhibitors (SSRis) are the first-line treatment for both PMS and PD when they manifest separately, but their co-occurrence often complicates the treatment. Our objectives were to evaluate the clinical picture of PMS, co-morbid with PD and the way it changes under 6-month SSRI treatment course. For that purpose, we conducted a longitudinal interventional study. We examined 30 women suffering from PMS and a current episode of PD, verified through premenstrual screening tool (PSST) and Mini International Neuropsychiatric Interview (M.I.N.I.6.0.), respectively. Before treatment initiation, irritability, mood lability, anxiety, breast tension and tenderness, changes in appetite, headaches, palpitations, and abdominal bloating were most common. The somatic symptoms were more than twice as common as the psychological. After 6 months of treatment, most of the symptoms mentioned above were still present but less severe. Forty per cent of the women recovered completely. It seems that in cases of comorbidity between PMS and PD, though somatic symptoms are more common, SSRIs are an effective option for managing both somatic and psychological symptoms.

Novel Uses of Selective Serotonin Reuptake Inhibitors in Women

2003 ◽  
Vol 16 (3) ◽  
pp. 191-199
Author(s):  
Shareen Y. El-Ibiary ◽  
Kelly C. Lee
Keyword(s):  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Hot Flashes ◽  
Premenstrual Dysphoric Disorder ◽  
Physical Symptoms ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
First Line Therapy ◽  
Current Therapies

Selective serotonin reuptake inhibitors (SSRIs) are commonly used as first-line therapy to treat mood disorders due to their demonstrated efficacy, safety, and tolerability profiles. SSRIs may play an intricate role in treating hormone-mediated disorders that disturb the quality of life for women. Selected uses of SSRIs, specifically in the treatment of hot flashes, premenstrual dysphoric disorder, and postpartum depression, are explored in this article. Data from several studies support the use of SSRIs in these conditions, and therefore, these agents have the potential to significantly improve mood, cognitive function, physical symptoms, and social functioning in patients with these disorders. In addition, SSRIs may prove to be viable alternatives to current therapies that may be contraindicated, poorly tolerated, or lack efficacy in patients with these disorders.

Sign in / Sign up

Export Citation Format

Share Document